I recently had the opportunity to present public testimony at a Food and Drug Administration (FDA) advisory panel for fribanserin, a medication currently being considered by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. This was not the first time a pharmaceutical company had attempted to get a medication approved for the indication of HSDD [2] in women with sexual dysfunction and most likely will not be the last [3]. My thoughts for this editorial are related to the patients we see every day, not the actual pharmaceutical product.
展开▼
